文献速递系统性红斑狼疮

系统性红斑狼疮共享决策辅助工具实施的患者结局:前瞻性实施研究

Patient outcomes from implementing a shared decision-making aid for systemic lupus erythematosus: a prospective implementation study.
PubMed 文献 · Lancet Rheumatol · 2025-09-17

该前瞻性实施研究在美国15家风湿科门诊纳入1895例系统性红斑狼疮(SLE)患者,在基线就诊时查看计算机化SLE患者决策辅助工具(完整版或精简版)。基线时患者决策冲突低(平均Low Literacy Decisional Conflict Scale评分19·5),82·8%的患者实际参与决策角色与偏好角色匹配,决策辅助工具的可接受性和可行性良好,且各结局评分在3个月和6个月随访时保持一致。

要点

  • 在美国15家风湿科门诊的1895例SLE患者中实施SLE患者决策辅助工具。
  • 基线时平均Low Literacy Decisional Conflict Scale评分为19·5(SD 23·8),决策冲突低。
  • 1631例参与者中1351例(82·8%)实际决策角色与偏好角色匹配。

核心结论

  • SLE患者决策辅助工具实施期间,包括共享决策和感知可接受性与可行性在内的患者结局良好或优秀,并在随访中持续。
  • 该决策辅助工具适用于所有SLE表现,并作为智能手机应用(ManageMyLupus)免费提供。

研究设计与样本

  • 前瞻性实施研究,在美国15家地理分布多样的风湿科门诊进行,注册号NCT03735238。
  • 2019年5月23日至2023年12月12日评估2005例SLE患者资格,纳入1895例;参与者平均年龄44·7岁(SD 14·4)。
  • 1855例有性别数据的应答者中1731例(93·3%)为女性、124例(6·7%)为男性;1832例有种族数据的应答者中827例(45·1%)为非裔美国人。
  • 参与者在基线常规门诊就诊时通过触摸屏平板、网站或智能手机应用查看决策辅助工具(随访时查看为可选),根据风湿科医生建议选择完整版或精简版。
  • 参与者在基线、3个月和6个月门诊就诊时完成经验证的计算机化调查,评估决策冲突、共享决策、医患沟通及感知可接受性与可行性。

主要发现

  • 基线查看决策辅助工具后患者结局良好或优秀,包括决策准备。
  • 平均Low Literacy Decisional Conflict Scale评分为19·5(SD 23·8)。
  • 1631例参与者中1351例(82·8%)使用控制偏好量表评估时实际治疗决策角色与偏好角色匹配。
  • 平均CollaboRATE评分为25·2(SD 4·1);平均医患沟通过程评分为82·2(SD 9·3)。
  • 1855例参与者中1510例(81·4%)认为决策辅助工具关于免疫抑制药物与糖皮质激素的信息平衡;各结局评分在3个月和6个月随访时保持一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on patient decision making for people with systemic lupus erythematosus (SLE) are scarce. We previously showed that an evidence-based SLE patient decision aid was more effective than the SLE information pamphlet provided by the American College of Rheumatology in reducing decisional conflict for the choice of immunosuppressive medications in women with lupus nephritis, with higher acceptability and feasibility. The aim of this study was to assess patient outcomes from the implementation of this SLE patient decision aid on disease management in people with SLE. METHODS: This prospective implementation study was done in 15 geographically diverse rheumatology clinics across the USA. Adults aged 18 years or older with a diagnosis of SLE identified based on a medical record review were included. There were no exclusion criteria. Participants were invited to view the computerised SLE patient decision aid, provided through a touchscreen tablet, a website, or a smartphone app during a regular clinic visit with their rheumatologist at baseline (viewing at follow-up visits was optional). Participants viewed either the full or abbreviated (lite) version, based on SLE disease activity and treatment, as recommended by their rheumatologist. Participants completed validated computerised surveys at each of the baseline, 3-month, and 6-month clinic visits on touchpad computers or their mobile phone (depending on patient preference). These surveys included questions related to patient decisional conflict, shared decision making, patient-physician communication, and perceived acceptability and feasibility of the decision aid. The main outcome of this study was to assess the impact of the SLE patient decision aid (both full and lite versions) on patient decisional conflict, shared decision making, patient-provider communication, and perceived acceptability and feasibility. The study had a multistakeholder committee that included people with lived experience of SLE. This study was registered at ClinicalTrials.gov, NCT03735238. FINDINGS: Between May 23, 2019, and Dec 12, 2023, 2005 patients with SLE were assessed for eligibility and 1895 were included in the study. Study participants had a mean age of 44·7 years (SD 14·4); of the 1855 respondents with data on sex, 1731 (93·3%) were female and 124 (6·7%) were male; of the 1832 respondents with data on race, 827 (45·1%) were African American. Patient outcomes were either good or excellent at the baseline visit after viewing the SLE patient decision aid, including preparation for decision making. The mean Low Literacy Decisional Conflict Scale score was low at 19·5 (SD 23·8); 1351 (82·8%) of 1631 participants matched with their preferred role versus their actual role in treatment decision making (using the control preferences scale); the mean CollaboRATE score was 25·2 (SD 4·1; for patient involvement in shared decision making); the mean patient-provider communication process score was 82·2 (SD 9·3); and 1510 (81·4%) of 1855 participants found the decision aid to be balanced for the information on immunosuppressive drugs versus glucocorticoids. Each outcome score remained consistent at follow-up visits at 3 and 6 months. INTERPRETATION: Patient outcomes, including shared decision making and perceived acceptability and feasibility of the decision aid, were either good or excellent and persisted during the implementation of a decision aid for patients with SLE. The decision aid is suitable for all SLE manifestations and is freely available as a smartphone app (ManageMyLupus). FUNDING: Patient-Centered Outcomes Research Institute.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Singh JA, Hearld LR, Eisen S, et al. Patient outcomes from implementing a shared decision-making aid for systemic lupus erythematosus: a prospective implementation study. Lancet Rheumatol. 2025. PMID: 40975111. doi:10.1016/S2665-9913(25)00130-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。